http://orcid.org/0000-0002-4610-8282
References
- Caly L, Druce JD, Catton MG, et al. The FDA approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Sharmeen S, Skrtic M, Sukhai MA, et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 2010;116(18):3593–3603.
- Bittencourt J, Meneses C, Gregianin L, et al. Uso compassivo de ivermectina em paciente com LMA refratária [A Compassive use of ivermectin in a patient with refractory AML]. Abstracts of the XIII Congresso Brasileiro de Oncologia Pediátrica, 2012. Rev Bras Hematol Hemoter. 2012;34:37. (Portuguese).
- Martin AFS, Junior CGC, Dufrayer MC, et al. Remissão Morfológica com uso compassivo de ivermectina, citarabina e fator estimulante de colônia de granulócitos em um adolescente com leucemia mieloide aguda refratária: Relato de Caso [Mophologic remission in a compassionate use with ivermectin, cytarabin and G-CSF in an adolescent with refractory AML: Case report]. Transfus Cell Ther 2018. Supplement S312 abstract 812 Portuguese. Available from: http://www.htct.com.br/index.php?p=revista&tipo=pdf-simple&pii=X2531137918631398.
- Chaccour C, Hammann F, Ramón-García S, et al. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156–1157.